Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02340156 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma
A Phase 2 study, sponsored by SynerGene Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT02340156: Clinical Trial Phase 2 study, sponsored by SynerGene Therapeutics.
NCT02340156 is a Phase 2 study that was terminated before completion, run by SynerGene Therapeutics. The registered enrollment target is 1 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02340156, a Phase 2 study, was terminated before completion, sponsored by SynerGene Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This Phase II clinical trial is an open label, single arm, multicenter study of the combination of intravenously administered SGT-53 and oral temozolomide in patients with confirmed glioblastoma who have proven tumor recurrence or progression. The objective of this trial is to assess 6 month progression free survival (PFS), overall survival (OS), anti-tumor activity, safety and possibly to evaluate, nanoparticle delivery to tumor site, and the induction of apoptosis in the tumor..
Primary Outcome
The 6 month progression-free survival (PFS) was evaluated using RANO Response Criteria.
Interventions
- DRUG Temozolomide
- GENETIC SGT-53
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2014-12 |
| Est. Completion | 2018-11 |
| Phase | Phase 2 |
Why NCT02340156 stopped before completion
NCT02340156 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Temozolomide is the first listed.
NCT02340156 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02340156 about?
NCT02340156 is a clinical study titled "Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma". This Phase II clinical trial is an open label, single arm, multicenter study of the combination of intravenously administered SGT-53 and oral temozolomide in patients with confirmed glioblastoma who have proven tumor recurrence or progression. The objective of this trial is to assess 6 month progres...
What is the current status of trial NCT02340156?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2014-12. Estimated completion is 2018-11.
What interventions are being tested in trial NCT02340156?
The interventions under investigation include: Temozolomide (DRUG), SGT-53 (GENETIC).
Who is sponsoring clinical trial NCT02340156?
This trial is sponsored by SynerGene Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02340156's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia